Directors' Dealings

5 February 2024

4basebio plc


(“4babsebio” or the "Company")
 

Directors’ Dealings

Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows:

Name Number of Shares Sold Sale price per share (p) Shareholding Following Sale Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet 45,322 660p 1,418,994 11.09%
David Roth 38,292 660p 457,708 3.58%

The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

4basebio PLC                +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson
Cavendish Capital Markets Limited (Broker) +44 (0)20 7220 0500
Geoff Nash/Charlie Beeson
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name
  1. Dr Heikki Lanckriet
  2. David Roth
2 Reason for notification
a. Position/Status
  1. CEO
  2. CFO
b. Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio plc
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code
Ordinary Shares

ISIN: GB00BMCLYF79
b. Nature of the transaction Sale of Ordinary Shares
Price(s) per share (p) Volume(s)
  1. 660p
  2. 660p

45,322

38,292

d. Aggregated information
  • Volume
  • Price
  • 83,614
  • 660 pence per share
e. Date of the transaction 2/2/2024
f. Place of the transaction London Stock Exchange, AIM



Companies

4basebio (4BB)
UK 100

Latest directors dealings